CBAY | CymaBay Therapeutics, Inc.

Index- P/E- EPS (ttm)-1.19 Insider Own0.31% Shs Outstand97.97M Perf Week10.06%
Market Cap906.94M Forward P/E- EPS next Y-1.15 Insider Trans-32.74% Shs Float80.92M Perf Month-8.37%
Income-107.00M PEG- EPS next Q-0.19 Inst Own76.30% Short Float / Ratio12.52% / 6.30 Perf Quarter9.55%
Sales- P/S- EPS this Y4.70% Inst Trans-1.08% Short Interest10.13M Perf Half Y178.40%
Book/sh1.06 P/B8.88 EPS next Y-9.60% ROA-59.10% Target Price14.20 Perf Year372.86%
Cash/sh2.45 P/C3.84 EPS next 5Y- ROE-151.30% 52W Range1.81 - 11.22 Perf YTD50.08%
Dividend- P/FCF- EPS past 5Y-8.90% ROI- 52W High-16.13% Beta0.27
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin- 52W Low419.89% ATR0.44
Employees63 Current Ratio5.20 Sales Q/Q- Oper. Margin- RSI (14)50.85 Volatility4.02% 4.64%
OptionableYes Debt/Eq0.91 EPS Q/Q7.10% Profit Margin- Rel Volume0.47 Prev Close9.30
ShortableYes LT Debt/Eq0.91 EarningsMay 15 AMC Payout- Avg Volume1.61M Price9.41
Recom1.50 SMA20-1.03% SMA50-0.46% SMA20049.27% Volume748,249 Change1.18%
Date Action Analyst Rating Change Price Target Change
Apr-05-23Initiated William Blair Outperform
Mar-09-23Initiated BTIG Research Buy $15
Apr-11-22Resumed Cantor Fitzgerald Overweight $9
Aug-04-20Reiterated H.C. Wainwright Buy $9 → $13
Jul-31-20Initiated Piper Sandler Overweight $12
May-26-20Upgrade H.C. Wainwright Neutral → Buy $9
May-12-20Upgrade SVB Leerink Mkt Perform → Outperform $6
May-12-20Upgrade Stifel Hold → Buy $4 → $8
May-12-20Upgrade ROTH Capital Neutral → Buy $15
May-12-20Upgrade Raymond James Mkt Perform → Outperform $7
May-19-23 05:59PM
May-16-23 11:06AM
May-15-23 04:04PM
May-10-23 08:00AM
08:00AM Loading…
May-09-23 08:00AM
Apr-28-23 07:00AM
Apr-26-23 10:01AM
Apr-21-23 08:00AM
Apr-17-23 08:00AM
Mar-29-23 08:50AM
Mar-28-23 09:55AM
Mar-20-23 09:04PM
Mar-18-23 08:31AM
Mar-16-23 04:04PM
04:05PM Loading…
Mar-09-23 04:05PM
Mar-01-23 08:00AM
Feb-06-23 08:00AM
Jan-30-23 08:00AM
Jan-24-23 07:00AM
Jan-23-23 04:11PM
Jan-17-23 08:50AM
Jan-08-23 12:00PM
Nov-23-22 10:40AM
Nov-17-22 09:40AM
Nov-14-22 04:06PM
Nov-07-22 04:05PM
Nov-04-22 08:00AM
Nov-03-22 08:00AM
Nov-01-22 08:01AM
09:58AM Loading…
Oct-13-22 09:58AM
Oct-05-22 09:40AM
Oct-03-22 08:00AM
Sep-14-22 08:00AM
Sep-06-22 08:02AM
Sep-05-22 12:00PM
Sep-01-22 10:17AM
Aug-30-22 01:29PM
Aug-24-22 08:00AM
Aug-16-22 09:55AM
Aug-12-22 04:30AM
Aug-11-22 04:05PM
Aug-04-22 04:05PM
Aug-02-22 11:17AM
Aug-01-22 08:00AM
Jun-22-22 08:00AM
Jun-09-22 06:14AM
Jun-08-22 08:00AM
May-23-22 12:43PM
May-13-22 12:00AM
May-12-22 04:06PM
May-11-22 08:00AM
May-06-22 09:37AM
May-05-22 04:01PM
Apr-24-22 11:05AM
Apr-22-22 04:47PM
Apr-20-22 09:26AM
Apr-04-22 08:00AM
Mar-23-22 06:13PM
Mar-17-22 04:25PM
Mar-10-22 04:05PM
Feb-10-22 08:00AM
Jan-24-22 05:38PM
Jan-22-22 06:00AM
Jan-11-22 12:00PM
Jan-04-22 01:38PM
Dec-16-21 09:14AM
Nov-19-21 09:47AM
Nov-18-21 08:00AM
Nov-17-21 04:33PM
Nov-15-21 08:00AM
Nov-11-21 09:00AM
Nov-10-21 05:35PM
Nov-04-21 08:00AM
Nov-03-21 04:05PM
Nov-01-21 07:07AM
Oct-06-21 11:21AM
Oct-01-21 08:00AM
Sep-02-21 07:38AM
Aug-30-21 08:00AM
Aug-12-21 11:00PM
Aug-05-21 04:01PM
Aug-02-21 10:29AM
Jul-26-21 11:18AM
Jul-20-21 09:10AM
Jun-30-21 02:26AM
Jun-21-21 08:00AM
Jun-14-21 08:00AM
Jun-09-21 08:00AM
May-18-21 08:00AM
May-17-21 08:30AM
May-13-21 04:06PM
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McWherter CharlesPresident of R&DMay 18Option Exercise5.0021,749108,74536,749May 19 06:00 PM
McWherter CharlesPresident of R&DMay 18Sale9.0821,749197,38715,000May 19 06:00 PM
Quinlan Paul TGeneral CounselMay 15Option Exercise2.945,00014,7005,000May 17 07:11 PM
Quinlan Paul TGeneral CounselMay 15Sale10.375,00051,8310May 17 07:11 PM
KIM DENNIS DChief Medical OfficerApr 17Option Exercise4.37112,219490,397132,219Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 17Sale9.54112,2191,070,53620,000Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 13Option Exercise4.377,78134,00327,781Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 13Sale8.987,78169,88020,000Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerMar 28Option Exercise4.3710043720,100Mar 30 05:39 PM
KIM DENNIS DChief Medical OfficerMar 28Sale8.9810089820,000Mar 30 05:39 PM
Shah SujalChief Executive OfficerJun 06Buy1.9551,301100,037171,301Jun 07 08:14 AM